Currently available NRF2 inhibitors exhibit systemic NRF2 inhibitory properties and subsequent off-target effects; e.g., systemic NRF2 inhibition reduces NRF2 levels not only in the tumor but also in the surrounding cells, including immune cells. The gene discussed is NFE2L2; the disease is neoplasm.